A Phase I Open Label, Safety And Preliminary Efficacy Study of MRx0518 In Combination With Pembrolizumab In Patients With Advanced Malignancies Who Have Progressed On PD-1 Inhibitors
Phase of Trial: Phase I
Latest Information Update: 21 Jan 2019
At a glance
- Drugs MRX 518 (Primary) ; Pembrolizumab (Primary)
- Indications Bladder cancer; Malignant melanoma; Non-small cell lung cancer; Renal cancer; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors 4D Pharma PLC
- 11 Jan 2019 Planned End Date changed from 30 Jun 2022 to 1 Mar 2024.
- 11 Jan 2019 Planned primary completion date changed from 31 May 2021 to 1 Mar 2023.
- 11 Jan 2019 Status changed from not yet recruiting to recruiting.